Cargando…
Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules
BACKGROUND: Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide, the lifetime risk of developing this disease is 1.5%. Motor diagnostic symptoms of PD are caused by degeneration of nigrostria-tal dopamine neurons. There is no cure for PD and current therapy is lim...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425072/ https://www.ncbi.nlm.nih.gov/pubmed/30182859 http://dx.doi.org/10.2174/1570159X16666180905094123 |
_version_ | 1783404778939744256 |
---|---|
author | Sidorova, Yulia A. Volcho, Konstantin P. Salakhutdinov, Nariman F. |
author_facet | Sidorova, Yulia A. Volcho, Konstantin P. Salakhutdinov, Nariman F. |
author_sort | Sidorova, Yulia A. |
collection | PubMed |
description | BACKGROUND: Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide, the lifetime risk of developing this disease is 1.5%. Motor diagnostic symptoms of PD are caused by degeneration of nigrostria-tal dopamine neurons. There is no cure for PD and current therapy is limited to supportive care that partially alleviates dis-ease signs and symptoms. As diagnostic symptoms of PD result from progressive degeneration of dopamine neurons, drugs restoring these neurons may significantly improve treatment of PD. METHOD: A literature search was performed using the PubMed, Web of Science and Scopus databases to discuss the pro-gress achieved in the development of neuroregenerative agents for PD. Papers published before early 2018 were taken into account. RESULTS: Here, we review several groups of potential agents capable of protecting and restoring dopamine neurons in cul-tures or animal models of PD including neurotrophic factors and small molecular weight compounds. CONCLUSION: Despite the promising results of in vitro and in vivo experiments, none of the found agents have yet shown conclusive neurorestorative properties in PD patients. Meanwhile, a few promising biologicals and small molecules have been identified. Their further clinical development can eventually give rise to disease-modifying drugs for PD. Thus, inten-sive research in the field is justified. |
format | Online Article Text |
id | pubmed-6425072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-64250722019-09-01 Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules Sidorova, Yulia A. Volcho, Konstantin P. Salakhutdinov, Nariman F. Curr Neuropharmacol Article BACKGROUND: Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide, the lifetime risk of developing this disease is 1.5%. Motor diagnostic symptoms of PD are caused by degeneration of nigrostria-tal dopamine neurons. There is no cure for PD and current therapy is limited to supportive care that partially alleviates dis-ease signs and symptoms. As diagnostic symptoms of PD result from progressive degeneration of dopamine neurons, drugs restoring these neurons may significantly improve treatment of PD. METHOD: A literature search was performed using the PubMed, Web of Science and Scopus databases to discuss the pro-gress achieved in the development of neuroregenerative agents for PD. Papers published before early 2018 were taken into account. RESULTS: Here, we review several groups of potential agents capable of protecting and restoring dopamine neurons in cul-tures or animal models of PD including neurotrophic factors and small molecular weight compounds. CONCLUSION: Despite the promising results of in vitro and in vivo experiments, none of the found agents have yet shown conclusive neurorestorative properties in PD patients. Meanwhile, a few promising biologicals and small molecules have been identified. Their further clinical development can eventually give rise to disease-modifying drugs for PD. Thus, inten-sive research in the field is justified. Bentham Science Publishers 2019-03 2019-03 /pmc/articles/PMC6425072/ /pubmed/30182859 http://dx.doi.org/10.2174/1570159X16666180905094123 Text en © 2019 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Sidorova, Yulia A. Volcho, Konstantin P. Salakhutdinov, Nariman F. Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules |
title | Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules |
title_full | Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules |
title_fullStr | Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules |
title_full_unstemmed | Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules |
title_short | Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules |
title_sort | neuroregeneration in parkinson’s disease: from proteins to small molecules |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425072/ https://www.ncbi.nlm.nih.gov/pubmed/30182859 http://dx.doi.org/10.2174/1570159X16666180905094123 |
work_keys_str_mv | AT sidorovayuliaa neuroregenerationinparkinsonsdiseasefromproteinstosmallmolecules AT volchokonstantinp neuroregenerationinparkinsonsdiseasefromproteinstosmallmolecules AT salakhutdinovnarimanf neuroregenerationinparkinsonsdiseasefromproteinstosmallmolecules |